CAREERS
Working at Risen
Job opportunities
Employee welfare
繁体
简体
Company news IP granted Publications
2024-11-13
PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.
PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.
Details
Year:
All 2024 2023 2022 2021 2020
2021-10-19
Risen signed a strategic cooperation agreement with China Merchants Bank Shanghai Branch
Detail
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb